Seagen

Seagen Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997, and is headquartered in Bothell, WA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Seagen reports robust Q4 earnings, poised for growth and innovation

Seagen's strong financial performance, focus on key products like ADCETRIS and PADCEV, and strategic investments in R&D position the company for continued growth.
While facing challenges in managing expenses and navigating competitive markets, Seagen's commitment to innovation and pipeline development presents opportunities for future success.
Overall, Seagen's performance in Q4 2022 reflects a company poised for growth, with a clear strategic focus on optimizing its commercial portfolio and advancing clinical programs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Seattle Genetics is a clinical-stage biotechnology company that focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in the pivotal trial for patients with relapsed or refractory Hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc.  The company was founded in 1997 and is headquartered in Bothell, Washington.

Insulet

These two stocks don't appear to be slowing down anytime soon.

2 Healthcare Stocks That Doubled in 2019 and Can Still Go Higher

With a newly approved drug and a candidate treatment that the FDA has given its “breakthrough” designation, there's good reason to expect revenue growth.

2 Things That Will Propel Seattle Genetics’ Stock Even Higher in 2020

Incyte

Few biotech companies ever reach that valuation, and if they do, you should snap them up for your portfolio.

A $20 Billion Sweet Spot in Biotech

Seattle Genetics (SGEN) submits an NDA to the FDA for tucatinib in combination with Herceptin and Xeloda seeking approval to treat locally advanced/metastatic HER2-positive breast cancer.

Seattle Genetics Submits NDA to FDA for Tucatinib Combo

AstraZeneca

BeiGene

The FDA was in a big hurry to make these new therapies available for patients who need them.

3 Blockbuster Cancer Drug Launches to Watch in 2020

The Food and Drug Administration on Wednesday approved Padcev as a treatment for metastatic urothelial cancer.

Seattle Genetics' stock rises on approval of bladder cancer drug

The FDA grants accelerated nod to Seattle Genetics' (SGEN) Padcev to treat urothelial cancer. It also assigns Breakthrough Therapy tag to tucatinib for advanced/metastatic HER2-positive breast cancer.

Seattle Genetics Gets Speedy FDA Nod for Bladder Cancer Drug

Seattle Genetics and Astellas Pharma gained accelerated approval for a bladder cancer treatment — prodding SGEN stock to pop Thursday. Seattle Genetics is a highly rated biotech company.

Why This Leading Biotech Stock Just Added To Its 99% Gain This Year

Seattle Genetics, Inc. (NASDAQ: SGEN) shares are advancing following an early approval for Padcev, an antibody conjugate therapy it is co-developing with Astellas Pharma Inc.

Seattle Genetics Drug For Difficult-To-Treat Urothelial Cancer Gets Early FDA Nod

Seattle Genetics Inc. (NASDAQ:SGEN) CEO Clay Siegall called new data from the study of the company’s breast cancer drug “stunning.

Seattle Genetics' Cancer Study Boosts Prospects, Takeover Appeal

Seattle Genetics: A Prudent Growth Story

Athenex

Promising new results in breast cancer will be presented at next week's San Antonio Breast Cancer Symposium. Here's what to look for.

2 Breast Cancer Fighting Stocks to Invest In

Merck

Seattle Genetics (SGEN) and Astellas team up with Merck for a late-stage study to evaluate the enfortumab vedotin and Keytruda combo in patients with previously untreated metastatic urothelial cancer.

Seattle Genetics, Astellas Tie Up With Merck for Cancer Study

Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock?

Seattle Genetics (SGEN) Up 15.7% Since Last Earnings Report: Can It Continue?

The company reported positive results in a late-stage trial for an important drug candidate.

Here's Why Seattle Genetics Stock Jumped 25.7% in October

Seattle Genetics (SGEN) incurs wider-than-expected loss in third-quarter 2019 but rides high on revenue beat.

Seattle Genetics (SGEN) Q3 Loss Widens, Revenues Top Mark

Seattle Genetics, Inc.'s (SGEN) CEO Clay Siegall on Q3 2019 Results - Earnings Call Transcript

MacroGenics

Merus

Zymeworks Inc

With Breast Cancer Awareness Month drawing to a close and the San Antonio Breast Cancer Symposium on the horizon, stay alert for breaking news from companies developing new treatments.

4 Stocks Battling Breast Cancer

NeoGenomics

These stocks have track records of success and plenty of growth ahead.

Three Cancer Treatment Stocks to Buy Right Now.

It's become clear that a heavily criticized acquisition was actually a very smart move.

Is Seattle Genetics a Good Biotech Stock to Buy Now?

Horizon Pharma

Winnebago

XPO Logistics

Written by: Harry Boxer Here are four stocks positioned right at key technical breakout points. Horizon Therapeutics Public Limited Company (HZNP) climbed 92 cents to $28.20 on 2.3 million shares Tuesday, more than 1 1/2 times its average volume.

4 Stocks Nearing Key Breakouts

Coty

PetMed Express

A variety of factors sent major benchmarks higher Monday.

Why PetMed Express, Seattle Genetics, and Coty Jumped Today

Bank of America

ServiceNow

Pinterest

Twitter

Pinterest, Bank of America, Service Now, Twitter and Seattle Genetics were our top stock trades for Tuesday. Here's what you need to know.

5 Top Stock Trades for Tuesday: PINS, BAC, TWTR, NOW & SGEN

Shares of cancer drug maker Seattle Genetics soared more than 17 percent on Monday morning following positive results for a new drug that fights aggressive breast cancers.

Seattle Genetics’ stock jumps 17% on breast cancer drug trial success

Positive clinical trial data for its breast cancer drug tucatinib has investors smiling.

News for Seagen Stock (SGEN)